Marker Therapeutics has commissioned a new facility in Texas. The site will produce specific MultiTAA multitumor T cells for Phase II clinical trials of candidate MT-401 for the treatment of acute myeloid leukemia, as well as for future studies of the potential use of the antigen to treat hematologic and solid tumors.